摘要
肿瘤标志物通常用于筛查、诊断和区分恶性疾病,但是特定的肿瘤标志物可能用于指示心力衰竭(HF)患者。在所有肿瘤标志物中,糖抗原125(CA125)是HF潜在的生化标志物,其与炎症因子、脑钠尿肽(BNP)的水平均呈显著相关。已有研究证明,CA125与HF患者的临床、血流动力学和超声心动图参数相关,能够提示HF的严重程度和预后,并且有助于评价治疗干预措施的效果。本文综述了近年来关于CA125和HF衰患者的研究进展。
Tumor biomarkers are used for screening, diagnosis and stratification of malignant diseases, but the role of some specific tumor markers has also been recently explored in patients with heart failure （HF）. Of all the tumor biomarkers, carbohydrate antigen125 （CA125） has emerged as a potential biomarker in HF due to its significant correlation with cytokines and brain natriuretic peptide （BNP） level. It has been demonstrated that CA125 is associated with clinical, hemodynamic and echocardiographic parameters indicative of the severity and therapeutic interventional effect of the disease. This article reviews research progress and clinical use of the tumor marker CA125 in patients with chronic HF.
出处
《心脏杂志》
CAS
2013年第6期731-734,共4页
Chinese Heart Journal
关键词
心力衰竭
糖抗原125
肿瘤标志物
炎症
heart failure
carbohydrate antigen-125
tumor markers
inflammation
